Sep 30, 2026 · 59 min
Strata bets on logistics as transplant technology fragments
Strata Critical Medical (SRTA): The Organ Transplant Logistics Roll-Up
Strata’s growth depends on whether its integrated logistics and clinical platform can capture expanding transplant pathways without taking on excessive asset or acquisition risk.
- 1Strata combines time-sensitive transport, organ recovery, and clinical services while remaining device-agnostic across evolving transplant technologies.
- 2Management sees mid- to high-single-digit organic growth, with additional upside from DCD donation, perfusion, recovery, and services per donor.
- 3Disciplined acquisitions and selective aircraft ownership support scale, but long-term value depends on free cash flow and operating performance.
Don't miss
Will Heyburn explains why Strata’s aircraft ownership is a strategic capability for selected opportunities, not a core requirement for growth.
The brief
Strata Critical operates where transplant medicine meets time-sensitive infrastructure, coordinating air and ground logistics, organ recovery, and clinical services across the U.S. ecosystem.
Will Heyburn and Mat Schneider describe a device-agnostic platform designed to serve transplant centers as technologies, donation pathways, and competitive structures evolve.
The company owns only about 30% of its aircraft, treating ownership as strategic leverage for selected contracts rather than a prerequisite for scaling.
Management sees baseline organic growth in the mid- to high-single digits, with further potential from DCD donors, perfusion, third-party recovery, and more services per donor.
The larger thesis is that fragmented future pathways—including new devices and potential xenotransplants—could make Strata’s logistics and clinical platform more valuable over time.
What was said on this episode
17 statements · 16 positive · 1 neutral
Strata’s clinical business grew more than 20% quarter over quarter recently.
“The clinical part of our business grew nearly 20%, more than 20% quarter over quarter in the most recent quarter.”
Listen at 4:31
Strata is adjusted EBITDA and free-cash-flow positive.
“We're adjusted EBITDA and free cash flow positive”
Listen at 4:38
Strata plans acquisitions to expand its national footprint alongside organic growth.
“we're executing incrementally to this strong organic growth on a plan of acquisitions to continue to build our national footprint”
Listen at 4:41
Strata’s integrated services can solve the organ-transplant supply problem.
“This is entirely a supply problem, and in our view, it's a supply problem that can be solved by putting the pieces of the puzzle together that we provide at Strata.”
Listen at 5:57
Strata believes it is unique in the transplant-services industry.
“we really believe we're one of a kind in this industry”
Listen at 7:59
Delaying aircraft activation until organ acceptance can reduce transplant logistics costs.
“we can save a lot of money for transplant centers and for the system if we wait to turn on expensive airplanes until we know that those organs are going to be utilized.”
Listen at 10:21
Normothermic regional perfusion produces 50% more usable organs per donor on average.
“resulting in, on average, 50% more usable organs per organ donor”
Listen at 11:43
Donation after circulatory death has grown around 20% annually in recent years.
“has been growing consistently in the 20% range over the last several years.”
Listen at 12:05
Organ allocation is planned to shift toward continuous distribution prioritizing patient sickness.
“The plan is to move to what's called continuous distribution, a national allocation methodology that focuses primarily on the sickness of the patient”
Listen at 12:49
Continuous distribution increased lung donor-recipient distances by nearly 80%.
“When we saw lungs move from acuity circles to continuous distribution, we saw a nearly 80% increase in the distance between donors and recipients.”
Listen at 13:01
Strata’s business model will benefit from faster-growing transplant segments and longer trips.
“our business model is more exposed to those faster-growing parts of the transplant industry and will benefit from those longer trips that we talked about”
Listen at 13:54
Strata has acquired four smaller regional players year to date.
“we've made 4 year to date of smaller regional players”
Listen at 14:51
Donor-recipient travel distances have increased about 68%.
“we've already seen about a 68% increase as these regulations have continued to evolve and as perfusion technology has allowed us to extend the distance that we can travel with these donor organs.”
Listen at 15:07
Strata is well capitalized and positioned to acquire quality regional providers.
“we're very well capitalized and we're very well positioned to find attractive, quality regional providers”
Listen at 17:08
Strata’s completed and pipeline acquisitions carry mid-single-digit EBITDA multiples.
“mid-single-digit adjusted EBITDA acquisition multiples for all of the acquisitions that we've completed to date and for everything that's in our pipeline today.”
Listen at 17:43
Strata continues to grow attractively, especially in clinical services.
“The company continues to grow attractively, particularly in our clinical business.”
Listen at 19:33
Strata’s transplant clinical business grew 22% organically and 27% including acquisitions quarter over quarter.
“You see 22% organic quarter-over-quarter growth, 27% when you include the benefit of our acquisitions on that transplant clinical business.”
Listen at 19:38
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Ian Cassel
Business BreakdownsListen to the full episode and explore every guest, topic, and moment on PodLume.